Skip to main content

Table 1 Baseline characteristics of the total population and according to randomized groups

From: Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training

 

All (n = 137)

Exercise (n = 52)

Control (n = 62)

Age (years)a

64 [41, 81]

65 [48, 81]

65 [41, 77]

Sex (male) n, (%)

115 (83.9)

45 (86.5)

50 (80.6)

BMIb (kg/m2)

28.7 (25.6, 31.6)

29.4 (25.6, 31.8)

28.3 (25.4, 31.5)

Duration of diabetes (years)

9 (5, 15)

11 (5, 15)

9 (5, 13)

Previous MIc, n (%)

62 (45.3)

20 (38.5)

31 (50.0)

Microvascular complicationsd

26 (19)

7 (13.5)

10 (16.1)

Advanced vascular diseasee, n (%)

85 (62.0)

28 (53.8)

40 (64.4)

Hypertension, n (%)

100 (73.0)

39 (75.0)

46 (74.2)

Current smokers, n (%)

23 (16.8)

9 (17.3)

9 (14.5)

HbA1c (%)

7.4 (6.8, 8.3)

7.4 (6.8, 8.4)

7.3 (6.8, 7.9)

Fasting blood glucose

8.1 (6.9, 9.8)

7.5 (6.7, 9.9)

8.0 (6.8, 9.6)

HOMA2-IRf

1.3 (0.7, 2.1)

1.1 (0.7, 1.9)

1.3 (0.7, 2.2)

Total cholesterol (mmol/L)

3.9 (3.4, 4.5)

3.8 (3.4, 4.3)

4 (3.3, 4.7)

Triglycerides (mmol/L)

1.4 (1.0, 1.9)

1.4 (1.1, 1.9)

1.4 (1.0, 1.9)

LDLg cholesterol (mmol/L)

2.0 (1.6, 2.6)

1.8 (1.5, 2.5)

2.1 (1.6, 2.7)

CRPh (mg/L)

2.6 (1.2, 5.0)

2.0 (0.9, 4.9)

2.4 (1.2, 5.0)

Medication

 RAAS inhibitors, n (%)

97 (70.8)

34 (65.4)

46 (74.2)

 Statins, n (%)

128 (93.4)

49 (94.2)

58 (93.5)

 Metformin, n (%)

101 (73.7)

40 (76.9)

46 (74.2)

 Sulfonylureas, n (%)

48 (35.0)

23 (44.2)

17 (27.4)

 Gliptin, n (%)

17 (12.4)

6 (11.5)

11 (17.7)

 Insulin, n (%)

26 (19.0)

10 (19.2)

12 (19.4)

 Antiplatelet medication, n (%)

129 (94.2)

47 (90.4)

61 (98.4)

  1. Data are presented as median (25, 75 percentiles) if not stated otherwise
  2. aMedian [min, max]
  3. bBody mass index
  4. cMyocardial infarction
  5. dMicrovascular complications were defined as a history of nephron-, neuro- or retinopathy, and/or abnormal monofilament test and/or (micro-) albuminuria
  6. eAdvanced vascular disease was defined as patients having previous myocardial infarction and/or diabetic microvascular complications in addition to coronary artery disease
  7. fGlucose and insulin values were entered in the computer model to calculate HOMA2-IR
  8. gLow-density lipoprotein
  9. hC-reactive protein